Drummond Michael, Chevat Catherine, Lothgren Mickael
Centre for Health Economics, University of York, UK.
Vaccine. 2007 Aug 10;25(32):5945-57. doi: 10.1016/j.vaccine.2007.04.070. Epub 2007 May 15.
Although many vaccination strategies are cost-effective, some of the newer vaccines are more expensive and may raise concerns about value for money. However, standard methods of economic evaluation may not adequately assess the true cost-effectiveness of vaccines, with the consequent under-application of vaccine strategies. Therefore, this paper reviews the evidence on cost-effectiveness of vaccines and vaccination strategies for pneumococcal disease, meningococcal disease, Hepatitis A and influenza. In each case the evidence is considered alongside existing vaccination policies in the major developed countries. The paper also highlights areas where traditional economic evaluations may not adequately reflect the value of vaccines.
尽管许多疫苗接种策略具有成本效益，但一些新型疫苗价格更高，可能会引发对性价比的担忧。然而，标准的经济评估方法可能无法充分评估疫苗的真正成本效益，从而导致疫苗策略应用不足。因此，本文回顾了关于肺炎球菌疾病、脑膜炎球菌疾病、甲型肝炎和流感的疫苗及疫苗接种策略成本效益的证据。在每种情况下，都会结合主要发达国家现有的疫苗接种政策来考虑这些证据。本文还强调了传统经济评估可能无法充分反映疫苗价值的领域。
